UNIRETIC
LOE ApproachingNDAORALTABLET
Approved
Jun 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UNIRETIC is an oral tablet small-molecule NDA approved in 1997 by UCB Pharma. The specific mechanism of action and indication are not publicly available in this dataset. Pharma professionals should note this is a mature product nearing loss of exclusivity.
LOE Approaching
With LOE approaching, the brand team is likely transitioning to defensive strategy and retention initiatives; headcount may shift toward generic preparation or portfolio rebalancing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked jobs and LOE approaching, career opportunities on UNIRETIC are contracting. Professionals considering this product should evaluate it as a defensive/maintenance role rather than a growth platform.
Brand ManagerField Sales Representative
Worked on UNIRETIC at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.